Addex Therapeutics Files 6-K, Incorporates Press Release
Ticker: ADXN · Form: 6-K · Filed: Apr 29, 2024 · CIK: 1574232
Sentiment: neutral
Topics: regulatory-filing, press-release, registration-statement
TL;DR
Addex Therapeutics filed a 6-K on 4/29/24, attaching a press release that's now part of their F-3 and S-8 filings.
AI Summary
On April 29, 2024, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This press release is relevant to their registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration No. 333-255124).
Why It Matters
This filing indicates ongoing corporate communications and regulatory compliance for Addex Therapeutics, potentially impacting investors' understanding of recent company developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily incorporates a previously issued press release, indicating standard corporate disclosure rather than a significant new event.
Key Numbers
- 001-39179 — SEC File Number (Identifies the specific SEC filing series for Addex Therapeutics Ltd.)
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- April 29, 2024 (date) — Filing date and press release date
- Exhibit 99.1 (document) — Incorporated press release
- Form F-3 (document) — Registration statement
- 333-255089 (registration_number) — Form F-3 registration number
- Form S-8 (document) — Registration statement
- 333-255124 (registration_number) — Form S-8 registration number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report that Addex Therapeutics Ltd. issued a press release on April 29, 2024, and to incorporate that press release (Exhibit 99.1) by reference into their existing registration statements.
What specific registration statements are mentioned in the filing?
The filing mentions incorporation by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statement on Form S-8 (Registration No. 333-255124).
When was the press release incorporated by this filing issued?
The press release incorporated by this filing was issued on April 29, 2024.
What is the SEC file number for Addex Therapeutics Ltd. referenced in this document?
The SEC file number for Addex Therapeutics Ltd. referenced in this document is 001-39179.
Does this filing contain new financial information or operational updates?
This filing itself does not contain new financial information or operational updates; it serves to incorporate a previously issued press release by reference.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-04-29 06:05:06
Filing Documents
- f6k_042924.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-002302.txt ( ) — 16KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On April 29, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated April 29, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: April 29, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated April 29, 2024